Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 5
Submit an article Journal homepage
266
Views
9
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone

Yi-Bin ChenDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USACorrespondence[email protected]
,
Ephraim P. HochbergDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
,
Yang FengDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
,
Donna NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
,
Bhupendra RawalDepartment of Biostatistics, Moffit Cancer Center, Tampa, FL, USA
,
Gabriela MotyckovaDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
,
David C. FisherDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
,
Steven L. McafeeDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
,
Thomas R. SpitzerDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
&
Ann S. LacasceDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
 show all
Pages 789-796 | Received 08 Dec 2009, Accepted 13 Feb 2010, Published online: 31 Mar 2010

References

  • Philip T, Guglielmi C, Hagenbeek A, et al Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
  • Bolwell B, Kalaycio M, Sobecks R, et al Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002;29:673–679.
  • Hamlin PA, Zelenetz AD, Kewalramani T, et al Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
  • Popat U, Przepiork D, Champlin R, et al High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998;16:63–69.
  • Vose JM, Sharp G, Chan WC, et al Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344–2352.
  • Ghesquieres H, Berger F, Felman P, et al Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006;24:5234–5241.
  • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
  • Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006;17(Suppl. 4):iv31–iv32.
  • Gisselbrecht C, Schmitz N, Mounier N, et al R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007;110(Suppl. 1): (Abstract 517).
  • Martin A, Conde E, Arnan M, et al R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829–1836.
  • Khouri IF, Saliba RM, Hosing C, et al Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240–2247.
  • Farhat MI, Karmali R, Gregory SA, et al Incorporating target immunotherapy into standard conditioning regimen prior to autologous stem cell transplantaion (ASCT) improves the transplant outcome for patients with relapsed/refractroy B cell non-Hodgkin lymphoma (B-NHL). Blood 2007;110(Suppl. 1): (Abstract 1911).
  • Tarella C, Zanni M, Magni M, et al Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. J Clin Oncol 2008;26:3166–3175.
  • Hoerr AL, Gao F, Hidalgo J, et al Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4561–4566.
  • Fenske TS, Hari PN, Carreras J, et al Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009;15:1455–1464.
  • Vose JM, Bierman PJ, Lynch JC, et al Autologous transplant event-free survival (EFS) following failure of CHOP-rituximab (CHOP-R) for diffuse large B-cell lymphoma (DLBCL) is the same as the EFS following failure of CHOP alone. Blood 2004;104(Suppl. 1): (Abstract 890).
  • Adegbola O, Andreadis S, Schuster J, et al Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2007;25(Suppl.): (Abstract 8122a).
  • Thakkar SG, Sweetenham JW, Rybicki L, et al Prior therapy with rituximab (R) in patients (pts) with diffuse large B-cell lymphoma (DLBCL) does not affect disease-free (DFS) or overall survival (OS) following high dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 2006;108(Suppl. 1): (Abstract 3054).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.